Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: Results from the SENTRY Antimicrobial Surveillance Program (1998–2003)
- 31 July 2005
- journal article
- Published by Elsevier BV in Diagnostic Microbiology and Infectious Disease
- Vol. 52 (3), 265-273
- https://doi.org/10.1016/j.diagmicrobio.2005.02.003
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Comparative activity and spectrum of broad-spectrum β-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002)Diagnostic Microbiology and Infectious Disease, 2003
- CefepimeAmerican Journal of Respiratory Medicine, 2003
- Risk Factors for Imipenem-Resistant Pseudomonas aeruginosa among Hospitalized PatientsClinical Infectious Diseases, 2002
- Acute Community-Acquired Pneumonia in Adults: Guidelines for Initial Antimicrobial Therapy Based on Local Evidence from a South American Working Group (ConsenSur)Journal of Chemotherapy, 2002
- Surveillance of antibiotic resistance in European ICUsJournal of Hospital Infection, 2001
- Resistance Patterns Among Nosocomial PathogensChest, 2001
- MONOTHERAPY VERSUS COMBINATION THERAPY FOR BACTERIAL INFECTIONSMedical Clinics of North America, 2000
- The Influence of Inadequate Antimicrobial Treatment of Bloodstream Infections on Patient Outcomes in the ICU SettingChest, 2000
- Emergence of Antibiotic-Resistant Pseudomonas aeruginosa : Comparison of Risks Associated with Different Antipseudomonal AgentsAntimicrobial Agents and Chemotherapy, 1999
- CefepimeDrugs, 1994